Aarey Drugs & Pharmaceuticals Ltd
Incorporated in 1990, Aarey Drugs & Pharmaceuticals Ltd is a manufacturer of API / Bulk Drugs and offers products for diverse
industrial applications[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Total Production Volume MT ・Standalone data |
|
|||||||
| Trading Revenue Share % of total revenue ・Standalone data |
||||||||
| Foreign Exchange Earnings (Exports) Rs. Lakh ・Standalone data |
||||||||
| Foreign Exchange Outgo (Imports) Rs. Lakh ・Standalone data |
||||||||
| Capacity Utilization % ・Standalone data |
||||||||
| Installed Manufacturing Capacity MT/year ・Standalone data |
||||||||
| R&D Capital Expenditure Rs. Lakh ・Standalone data |
||||||||
| Number of Manufactured Products count ・Standalone data |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
-
Closure of Trading Window
26 Jun - Trading window closes from July 1, 2026 until 48 hours after Q1 FY27 results.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Jun
-
Statement Of Deviation & Variation
30 May - Board approved audited standalone FY2026 results on 30 May 2026; audit opinion unmodified.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - FY26 secretarial compliance report notes multiple SEBI non-compliances, including warrant disclosure, related party filing delays, and penalties.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ADPL does manufacturing of active pharmaceutical ingredients, intermediates, specialty chemicals, and trading of industrial solvents & chemicals. It caters to pharmaceuticals formulation manufacturers and pharmaceutical merchant exports.